SAN MATEO, Calif. and SINGAPORE, March 08, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will be hosting a virtual research and development day on Thursday, March 16, 2023, from 10:00 am – 11:30 am ET.
The event will feature Key Opinion Leader (KOL) Brett King, MD PhD (Yale University School of Medicine) who will discuss the unmet medical need and current limited treatments for patients suffering from alopecia areata (AA), a common autoimmune disease characterized by loss of immune privilege (IP) in the hair follicle, and is driven by the activation and proliferation of interferon gamma (IFN-γ)-secreting immune cells which mediate the attack of hair follicles, resulting in complete or partial hair loss on the scalp and body.
ASLAN's leadership team including Carl Firth PhD (CEO), Stephen Doyle (Chief Business Officer), Alex Kaoukhov MD (Chief Medical Officer) and other members of the senior R&D management team will then provide an update on its recently announced clinical program to investigate farudodstat, a novel, oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH), in a Phase 2 proof-of-concept trial, as a potential first-in-class treatment for AA. Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model. ASLAN plans to initiate a proof-of-concept study of farudodstat in AA in the second quarter of 2023.
A live question and answer session will follow the formal presentations. To register for the event, please click here. A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN's website.
Brett King, MD PhD, is Associate Professor of Dermatology at Yale University, specializing in inflammatory skin diseases. He has pioneered the use of Janus kinase (JAK) inhibitors in dermatology, in particular for alopecia areata, vitiligo, atopic dermatitis, granuloma annulare, sarcoidosis, erosive lichen planus, and other disorders.
About farudodstat
Farudodstat is a potent, oral DHODH inhibitor that suppresses immune cell proliferation and IFN-γ secretion by blocking de novo production of pyrimidines required for DNA replication. Compared to first-generation DHODH inhibitors, farudodstat has been shown to be approximately 30 times more potent in its inhibition of DHODH and limiting T cell activity and has a well-tolerated safety profile. ASLAN has generated data showing that farudodstat can protect against the loss of immune privilege in hair follicles, supporting its potential as a first-in-class, safe and effective treatment option for alopecia areata (AA).
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in the global Phase 2b TREK-AD trial in moderate-to-severe atopic dermatitis (AD) patients and the Phase 2 TREK-DX trial in dupilumab-experienced AD patients. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme DHODH, in alopecia areata and plans to initiate a Phase 2 proof-of-concept trial in the second quarter of 2023. ASLAN has a team in California and in Singapore. For additional information please visit or follow ASLAN on LinkedIn.
Forward looking statements
This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, the timing, terms and completion of the proposed private placement; the expected gross proceeds from the proposed private placement and any additional proceeds that may be received by the Company upon exercise, if any, of the warrants issued in the private placement; statements regarding the Company's business strategy and clinical development plans; the Company's plans to develop and commercialize eblasakimab and farudodstat; the safety and efficacy of eblasakimab and farudodstat; the Company's plans and expected timing with respect to clinical trials, clinical trial enrolment and clinical trial results for eblasakimab and farudodstat; the potential of eblasakimab as a first-in-class treatment for atopic dermatitis and of farudodstat as a treatment for autoimmune disease; and the Company's cash runway. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations, or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic or the ongoing conflict between Ukraine and Russia on the Company's business and the global economy; general market conditions; changes in the competitive landscape; and the Company's ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company's SEC filings and reports (Commission File No. 001- 38475), including the Company's Annual Report on Form 20-F filed with the SEC on March 25, 2022. All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.
ASLAN Media and IR contacts
Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com
| Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
加利福尼亞州聖馬特奧新加坡,2023年3月8日(環球通訊社)--阿斯蘭製藥公司(納斯達克:ASLN)是一家致力於臨床階段、專注於免疫學的生物製藥公司,正在開發創新的治療方法以改變患者的生活,該公司今天宣佈,將於2023年3月16日(星期四)上午10:00-11:30舉辦虛擬研發日。
本次活動將由耶魯大學醫學院醫學博士、關鍵意見領袖佈雷特·金主持,他將討論斑禿(AA)患者尚未得到滿足的醫療需求和目前有限的治療方法。斑禿是一種常見的自身免疫性疾病,其特徵是毛囊中失去免疫豁免權(IP),由分泌幹擾素-γ的免疫細胞激活和增殖推動,這種免疫細胞介導毛囊的攻擊,導致頭皮和身體完全或部分脫髮。
阿斯蘭的領導團隊包括Carl Firth博士(首席執行官)、Stephen Doyle(首席商務官)、Alex Kaoukhov MD(首席醫療官)和高級研發管理團隊的其他成員,然後將提供其最近宣佈的臨床計劃的最新情況法度他汀,一種新型的口服二氫羅酸脫氫酵素(DHODH)抑制劑,在第二階段概念驗證試驗中,作為治療再生障礙性貧血的潛在一流療法。Farudodstat在人類AA疾病模型中,已被證明抑制幹擾素-γ的分泌,減少免疫細胞的增殖,並潛在地保護毛囊免受IP崩潰的影響。阿斯蘭計劃啟動一項概念驗證研究法度他汀在2023年第二季度的AA中。
在正式演講之後,將有現場問答環節。要註冊參加活動,請單擊此處。活動的重播和演示材料將在阿斯蘭網站的投資者關系部分獲得。
佈雷特·金,國防部博士,耶魯大學皮膚科副教授,專門研究炎症性皮膚病。他率先在皮膚科使用Janus Kinase(JAK)抑制劑,特別是治療斑禿、白癜風、特應性皮膚炎、環狀肉芽腫、結節病、侵蝕性扁平苔蘚和其他疾病。
關於法度他汀
Farudodstat是一種有效的口服脫氫表雄酯酮抑制劑,通過阻斷免疫細胞增殖和幹擾素-γ的分泌而抑制免疫細胞的增殖從頭開始DNA複製所需的嘧啶的生產。與第一代DHODH抑制劑相比,法度他汀已被證明在抑制DHODH和限制T細胞活性方面的效力約為30倍,並且具有良好的耐受性。阿斯蘭生成的數據顯示,法度他汀可防止毛囊失去免疫豁免權,支持其作為一流、安全有效的斑禿(AA)治療方案的潛力。
阿斯蘭製藥公司簡介
阿斯蘭製藥公司(納斯達克代碼:ASLN)是一家專注於免疫學的臨床階段生物製藥公司,正在開發創新的治療方法,以改變患者的生活。阿斯蘭目前正在評估。Eblasakimab,一種潛在的針對IL-13受體的一流抗體,在全球中重度特應性皮膚炎(AD)患者的2b期Trek-AD試驗和2003年的2期Trek-DX試驗中被髮現杜匹魯單抗-有經驗的AD患者。阿斯蘭也在開發法度他汀,是治療斑禿的酵素DHODH,的高效口服藥物抑制劑,並計劃在2023年第二季度啟動第二階段概念驗證試驗。Aslan在加利福尼亞州和新加坡有一個團隊。欲瞭解更多資訊,請訪問或關注LinkedIn上的Aslan。
前瞻性陳述
本新聞稿包含前瞻性陳述。這些陳述是基於阿斯蘭製藥有限公司和/或其附屬公司(“本公司”)管理層目前的信念和預期。這些前瞻性陳述可能包括但不限於:擬定向增發的時間、條款和完成情況;擬定向增發的預期總收益以及公司行使定向增發認股權證後可能獲得的任何額外收益(如果有的話);有關公司業務戰略和臨床發展計劃的陳述;公司開發和商業化的計劃。Eblasakimab和法度他汀的安全性和有效性。Eblasakimab和法度他汀;該公司關於#年的臨床試驗、臨床試驗登記和臨床試驗結果的計劃和預期時間Eblasakimab和法度他汀;潛在的Eblasakimab作為特應性皮膚炎的一流治療方法法度他汀作為治療自身免疫性疾病的藥物;以及該公司的現金跑道。公司的估計、預測和其他前瞻性陳述是基於管理層對未來事件和趨勢的當前假設和預期,這些事件和趨勢影響或可能影響公司的業務、戰略、運營或財務業績,本質上涉及重大已知和未知風險和不確定因素。由於許多風險和不確定性,實際結果和事件的時間可能與前瞻性表述中預期的大不相同,這些風險和不確定性包括:在臨床前或臨床研究期間觀察到的意想不到的安全性或有效性數據;臨床站點激活率或臨床試驗註冊率低於預期;新冠肺炎大流行或烏克蘭與俄羅斯之間持續的衝突對公司業務和全球經濟的影響;總體市場狀況;競爭格局的變化;以及公司獲得足夠資金為其戰略和臨床發展計劃提供資金的能力。其他可能導致實際結果與前瞻性陳述中明示或暗示不同的因素在公司提交給美國證券交易委員會的檔案和報告(委員會檔案第001-38475號)中有所描述,包括公司於2022年3月25日提交給美國證券交易委員會的Form 20-F年度報告。除歷史事實以外的所有陳述均為前瞻性陳述。“相信”、“可能”、“將”、“目標”、“估計”、“繼續”、“預期”、“打算”、“預期”、“計劃”或這些術語的否定,以及表達未來事件或結果不確定性的類似表達,旨在識別估計、預測和其他前瞻性陳述。估計、預測和其他前瞻性陳述僅說明它們作出之日的情況,除法律要求的範圍外,公司沒有義務更新或審查任何估計、預測或前瞻性陳述。
阿斯蘭媒體和IR聯繫人
艾瑪·湯普森 SPurwing通信 電話:+6562067350 電子郵件:aslan@spurwingcoms.com
| 阿什利·R·羅賓遜 生活科學顧問有限責任公司 電話:+1(617)430-7577 電子郵件:arr@lifescivisors.com。 |